BRPI1010861A8 - métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica - Google Patents

métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica

Info

Publication number
BRPI1010861A8
BRPI1010861A8 BRPI1010861A BRPI1010861A BRPI1010861A8 BR PI1010861 A8 BRPI1010861 A8 BR PI1010861A8 BR PI1010861 A BRPI1010861 A BR PI1010861A BR PI1010861 A BRPI1010861 A BR PI1010861A BR PI1010861 A8 BRPI1010861 A8 BR PI1010861A8
Authority
BR
Brazil
Prior art keywords
osteoarthritis
inflammation
pain
methods
package
Prior art date
Application number
BRPI1010861A
Other languages
English (en)
Inventor
Charles Mayo John
Langton Iliffe George
Vierl Ulrich
Rother Matthias
Original Assignee
Langton Iliffe George
Vierl Ulrich
Idea Ag
Charles Mayo John
Targeted Delivery Tech Limited
Sequessome Tech Holdings Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42785828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1010861(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Langton Iliffe George, Vierl Ulrich, Idea Ag, Charles Mayo John, Targeted Delivery Tech Limited, Sequessome Tech Holdings Limited filed Critical Langton Iliffe George
Publication of BRPI1010861A2 publication Critical patent/BRPI1010861A2/pt
Publication of BRPI1010861A8 publication Critical patent/BRPI1010861A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FORMULAÇÃO VESICULAR PARA USO NO TRATAMENTO DE DOR, INFLAMAÇÃO OU OSTEOARTRITE. Trata-se de formulações vesiculares aqui apresentadas que compreendem um ou mais fosfolipídios e um mais tensoativos não-iônicos que são eficazes no tratamento de dor, inflamação ou osteoartrite, mais especificamente no tratamento e outra dor em tecido profundo, por exemplo, osteoartrite e outra dor em articulação ou músculo, bem como métodos para tratamento de dor, inflamação ou osteoartrite, mais especificamente no tratamento de dor em tecido profundo, por exemplo osteoartrite e outra dor em articulação ou músculo com o uso das mesmas.
BRPI1010861A 2009-06-03 2010-06-03 métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica BRPI1010861A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18395609P 2009-06-03 2009-06-03
US31447810P 2010-03-16 2010-03-16
US32014810P 2010-04-01 2010-04-01
PCT/IB2010/001557 WO2010140061A2 (en) 2009-06-03 2010-06-03 Formulations for the treatment of deep tissue pain

Publications (2)

Publication Number Publication Date
BRPI1010861A2 BRPI1010861A2 (pt) 2018-06-12
BRPI1010861A8 true BRPI1010861A8 (pt) 2023-01-24

Family

ID=42785828

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010861A BRPI1010861A8 (pt) 2009-06-03 2010-06-03 métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica

Country Status (25)

Country Link
US (2) US20120220669A1 (pt)
EP (1) EP2437726B1 (pt)
JP (2) JP2012528846A (pt)
KR (1) KR20140021950A (pt)
CN (4) CN102639113A (pt)
AU (1) AU2010255391C1 (pt)
BR (1) BRPI1010861A8 (pt)
CA (1) CA2764227C (pt)
CL (1) CL2011003065A1 (pt)
CO (1) CO6480985A2 (pt)
DE (1) DE112010001765T5 (pt)
DK (1) DK2437726T3 (pt)
EA (1) EA029132B1 (pt)
ES (1) ES2682075T3 (pt)
GB (1) GB2483419B (pt)
IL (1) IL216737A (pt)
LT (1) LT2437726T (pt)
MX (1) MX349417B (pt)
MY (1) MY170121A (pt)
NZ (1) NZ597419A (pt)
PL (1) PL2437726T3 (pt)
PT (1) PT2437726T (pt)
SG (1) SG176297A1 (pt)
WO (1) WO2010140061A2 (pt)
ZA (1) ZA201200017B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598906A (en) * 2009-08-21 2014-08-29 Targeted Delivery Technologies Ltd Vesicular formulations
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
GB201206486D0 (en) * 2012-04-12 2012-05-30 Sequessome Technology Holdings Ltd Vesicular formulations and uses thereof
GB201208384D0 (en) 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, uses and methods
GB201208409D0 (en) * 2012-05-14 2012-06-27 Sequessome Technology Holdings Ltd Vesicular formulations, kits and uses
SG11201600424VA (en) * 2013-07-31 2016-02-26 Sequessome Technology Holdings Ltd Vesicles
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201505532D0 (en) * 2015-03-31 2015-05-13 Sequessome Technology Holdings Ltd Formulations
LT3316857T (lt) 2015-06-30 2021-11-25 Sequessome Technology Holdings Limited Daugiafazės kompozicijos
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
CN114507408A (zh) * 2022-03-02 2022-05-17 陕西科技大学 一种低摩擦、模量可调的物理水凝胶及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2067754C (en) 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
JPH08509202A (ja) * 1992-07-08 1996-10-01 ディアノルム―ゲレーテ・ゲー・マイエルホファー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リポソーム、それを調製する方法及び薬調製におけるその用途
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
KR20010106462A (ko) * 1998-09-01 2001-11-29 체에베체 그레고르 배리어를 가로지른 대전 침투제의 전기적으로 제어된수송
JP2002533379A (ja) * 1998-12-23 2002-10-08 イデア アクチェンゲゼルシャフト 生体内における局所的に非侵襲性である用途のための改善された製剤
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
TWI281407B (en) * 2000-09-18 2007-05-21 Vasogen Ireland Ltd Apoptosis-mimicking synthetic entities and use thereof in medical treatment
EP1230917A1 (de) * 2001-02-08 2002-08-14 Vectron Therapeutics AG Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung
US20040009216A1 (en) * 2002-04-05 2004-01-15 Rodrigueza Wendi V. Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
JP2004131432A (ja) * 2002-10-11 2004-04-30 Kumamoto Technology & Industry Foundation 悪性腫瘍抑制剤
US7473432B2 (en) 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
EP1551370B1 (en) * 2002-10-11 2007-12-19 Idea Ag Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
WO2004098524A2 (en) * 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
CA2533084A1 (en) * 2003-07-21 2005-01-27 Vasogen Ireland Limited Liposomes containing phosphate glycerol groups for treating acute inflammatory condition
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
JP5660561B2 (ja) * 2006-09-28 2015-01-28 ハダシット メディカルリサーチサービセス アンド ディベロップメント リミテッド ジョイント部の潤滑に関するグリセロリン脂質の使用

Also Published As

Publication number Publication date
IL216737A (en) 2016-09-29
IL216737A0 (en) 2012-02-29
MX2011012754A (es) 2012-07-25
EP2437726A2 (en) 2012-04-11
JP2015193629A (ja) 2015-11-05
CN105434354A (zh) 2016-03-30
KR20140021950A (ko) 2014-02-21
CN102639113A (zh) 2012-08-15
CA2764227A1 (en) 2010-12-09
CO6480985A2 (es) 2012-07-16
AU2010255391C1 (en) 2016-10-27
NZ597419A (en) 2014-01-31
CA2764227C (en) 2016-12-06
SG176297A1 (en) 2012-01-30
WO2010140061A2 (en) 2010-12-09
MY170121A (en) 2019-07-05
EA029132B1 (ru) 2018-02-28
ES2682075T3 (es) 2018-09-18
GB201122433D0 (en) 2012-02-08
JP2012528846A (ja) 2012-11-15
CN105434329A (zh) 2016-03-30
DE112010001765T5 (de) 2012-12-27
CN105434353A (zh) 2016-03-30
EP2437726B1 (en) 2018-05-16
EA201190344A1 (ru) 2012-09-28
PT2437726T (pt) 2018-08-10
ZA201200017B (en) 2019-01-30
CL2011003065A1 (es) 2012-08-31
BRPI1010861A2 (pt) 2018-06-12
AU2010255391A1 (en) 2012-02-02
AU2010255391B2 (en) 2016-06-02
MX349417B (es) 2017-07-28
US20120220669A1 (en) 2012-08-30
GB2483419B (en) 2015-04-08
WO2010140061A3 (en) 2011-07-28
LT2437726T (lt) 2018-09-10
PL2437726T3 (pl) 2018-12-31
GB2483419A (en) 2012-03-07
US20160175448A1 (en) 2016-06-23
DK2437726T3 (en) 2018-08-13

Similar Documents

Publication Publication Date Title
BRPI1010861A8 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
ES2544967T3 (es) Formulación y método para la prevención y el tratamiento de las metástasis óseas o de otras enfermedades óseas
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
MX2013006040A (es) Antagonistas del receptor de acido lisofosfatidico y su uso en el tratamiento de fibrosis.
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
BR112014016672A2 (pt) compostos de carbamato e sua preparação e uso
BR112013026032A2 (pt) composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida
BR112012022187A2 (pt) tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
NO20064584L (no) Tetrahydropyridoindolderivater
CR8778A (es) Revestimientos de azucar y metodos para estos
BR112012005225B8 (pt) Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201390772A1 (ru) Новые соли и полиморфные формы афатиниба
ECSP12011962A (es) Tratamientos para trastornos gastrointestinales
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
BR112014008700A2 (pt) composições úteis no tratamento de nefropatia e processos para preparação das mesmas
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
UY28271A1 (es) Compuestos químicos
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
GB201206486D0 (en) Vesicular formulations and uses thereof
CR20110226A (es) Composición para tratar enfermedad

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDEA AG (DE) ; TARGETED DELIVERY TECHNOLOGIES LIMITED (MT)

B25A Requested transfer of rights approved

Owner name: TARGETED DELIVERY TECHNOLOGIES LIMITED (MT)

B25A Requested transfer of rights approved

Owner name: SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT)